CS-02 is under clinical development by Center Laboratories and currently in Phase II for Type 2 Diabetes. According to GlobalData, Phase II drugs for Type 2 Diabetes have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CS-02’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CS-02 is under development for the treatment of type 2 diabetes. The drug candidate is a tablet formulation administered orally. The drug candidate is a calcium channel blocker.
Center Laboratories overview
Center Laboratories subsidiary of ALK-Abello AS, is an oral solution pharmaceutical company that develops, manufactures and markets oral medical solutions. The company’s products include CNS drugs, drugs for diabetes. It provides solutions to special medication needs of infants, young children, the elderly, patients with dysphagia and special population. Center Laboratories also develops drugs for pain treatment. Center Laboratories also develop new formulations of oral solutions. The company offers clinical, regulatory, production and marketing services. It provides new drug development of specialty drugs for unmet medical needs. Center Laboratories is headquartered in Taipei, Taiwan
For a complete picture of CS-02’s drug-specific PTSR and LoA scores, buy the report here.